Peptide market buzzing

Peptides are short chains of amino acids — the same building blocks as proteins — and a surge in obesity drugs has turned them into one of biotech’s hottest manufacturing bets. (fda.gov) The biggest commercial proof point is already on the market: semaglutide and tirzepatide, the active ingredients in Wegovy and Zepbound, are peptide-based drugs used for weight loss and diabetes. The Food and Drug Administration says semaglutide is a glucagon-like peptide-1 receptor agonist, and it approved Zepbound for chronic weight management in December 2023. (fda.gov, fda.gov) Market researchers now put the peptide therapeutics business well into nine figures. Grand View Research estimated the global market at $140.86 billion in 2025, while Fortune Business Insights put it at $131.95 billion in 2025 and projected $146.34 billion in 2026. (grandviewresearch.com, fortunebusinessinsights.com) That helps explain why social-media claims about a “$200 billion” peptide opportunity are finding an audience: some published forecasts already point toward roughly $295 billion to $335 billion later in the next decade. Those figures come from commercial market reports, not audited company filings, but they show why investors are treating peptides as a scale story rather than a niche drug format. (grandviewresearch.com, fortunebusinessinsights.com) The money is moving first into factories. CordenPharma said on July 16, 2024 that it would invest about €900 million over three years to expand peptide manufacturing in the United States and Europe, tied to what it called growing demand for glucagon-like peptide-1 medicines. (cordenpharma.com) CordenPharma raised that number in March 2025, saying total peptide-platform investment would exceed €1 billion and that the build-out was aimed at pushing peptide-platform sales past €1 billion by 2028. The company also announced a long-term supply deal with Viking Therapeutics in March 2025 to support its peptide drug candidate VK2735. (cordenpharma.com, cordenpharma.com) Bachem, another major peptide manufacturer, reported 2025 sales growth of 21.8% in Swiss francs and an earnings margin of 30.9% before depreciation and amortization. It told investors in March 2026 that the peptide and oligonucleotide market remained “very attractive,” with high-volume demand pushing the need for bigger, more efficient plants. (bachem.com, bachem.com) The bull case online leans on those margins and on the idea that peptide production can be scaled faster than older biologic drug manufacturing. PolyPeptide, a listed contract manufacturer, told investors in its 2025 annual report that more than 80% of roughly 800 peptide drug projects in development are estimated to be made synthetically, and that the business has high barriers to entry and high switching costs. (report.polypeptide.com) The food side is earlier and less defined. The Good Food Institute said in its 2024 fermentation industry report that new fermentation-enabled products reached supermarket shelves in 2024, while its March 2025 market deck said precision fermentation is being used to make proteins and functional ingredients for foods ranging from dairy alternatives to collagen-like ingredients. (gfi.org, gfi.org) That means the peptide frenzy is really two stories at once: a drug market with approved blockbusters and a food-tech market still proving demand and cost. The numbers behind the excitement are real enough to drive billion-euro factory plans, but the valuations circulating online still depend on how much of that demand turns into durable contracts and commercial products. (fda.gov, cordenpharma.com, bachem.com)